Therapeutic effects of adriamycin combined with high-intensity focused ultrasound on osteosarcoma.
To analyze the efficacy of adriamycin (ADM) combined with high-intensity focused ultrasound (HIFU) in patients with osteosarcoma. A total of 72 patients with osteosarcoma were selected and divided into the control group (n=36) and the observation group (n=36). Patients in the control group were treated with ADM, while those in the observation group received HIFU in addition to ADM. The efficacy and adverse reactions in the observation and control group were compared. The response rate and disease control rate in the observation group were significantly higher than those in the control group (p<0.05). No significant difference was found in the survival rate at year 1 after treatment between the two groups, but the observation group had overtly higher survival rates at years 2 and 3 after treatment in comparison with the control group (p<0.05). There was no obvious difference in the incidence rate of adverse reactions between the observation and control group. After treatment, the levels of serum tumor necrosis factor-alpha (TNF-α), interleukin-2 (IL-2) and IL-8 in the observation group were clearly higher than those in the control group. Serum alkaline phosphatase (ALP) and creatinine (Cr) in the observation and control group showed no significant differences. Compared with the control group, ALP level was significantly decreased in the observation group (p<0.05). The limb function and psychological behavior after treatment in the observation group were significantly superior to those in the control group (p<0.05). The application of ADM combined with HIFU is conducive to improving efficacy on osteosarcoma, prolonging survival and improving prognosis.